Lilly and Incyte's Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time
Shots:
- The companies shared the additional efficacy and safety data of the ACTT-2 study demonstrating baricitinib + remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir as monothx
- The biggest benefits were observed in patients requiring supplemental oxygen (grade 5 on the eight-point ordinal scale) and those who required high-flow oxygen/non-invasive ventilation (grade 6) at baseline
- Additionally- Eli Lilly is in talks with the US FDA for EUA of baricitinib (JAK1/JAK2 inhibitor licensed to Lilly from Incyte) to treat hospitalized patients with COVID-19
Ref: Eli Lilly | Image: Strateos Blog
Related News: Eli Lilly and Incyte’s Olumiant + Gilead’s Veklury Reduce Time to Recovery in Hospitalized Patients with COVID-19
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
